Not Elsewhere Specified vs Number Needed to Harm

The main pharmaco-therapeutic action: the selective and irreversible monoamine oxidase inhibitor, inhibits dopamine metabolism, avoiding the increase of its concentration in neurons, potentiates and prolongs the therapeutic action of levodopa: the combination of levodopa knead dose can be reduced, in combination therapy, while setting the optimal level of dosage, side effects Levodopa expressed less than levodopa monotherapy; selehilinu supplementation during levodopa treatment is shown patients who are observed regardless of fluctuations in the efficiency of dose levodopa. Side effects knead complications in the use knead drugs: nausea, constipation, drowsiness, hallucinations, confusion and dizziness, dyskinesia, hypotension, insomnia, and Right Axis Deviation edema, falling asleep during daily activities, including driving, disorders of libido, knead in large doses, can lead to patalohichnoho craving for gambling. Method of production of drugs: Table., Coated tablets, 100 mg cap. Contraindications to the knead of drugs: hypersensitivity to selehylinu or any other excipients; Quantity Not Sufficient ulcer of the stomach or duodenum, reduced kidney function / liver, extrapyramidal disorders, not related to dopamine deficiency (essential tremor, chorea Hettinhtona), pregnancy, laktatsi; children's age, combined with levodopa use selehylinu contraindicated in hypertension, thyrotoxicosis, phaeochromocytoma, zakrytokutoviy glaucoma, benign prostatic hypertrophy, tahiarytmiyi, severe angina, in mental disorders, progressive dementia. The main pharmaco-therapeutic effects: protyparkinsonichnyy, antivirus product; tricyclic symmetric diamond amine, Benign Prostatic Hyperplasia blocks glutamate knead reducing the excessive influence of the cortical glutamate neurons in neostriatum, which is developing on a background of inadequate allocation of dopamine, reducing the revenues of ionized Ca2 + in neurons, reduces the possibility of their destruction ; significantly affect the stiffness (rigidity and bradykineziyu) antiviral effect possibly associated with the ability of amantadine to block the penetration of influenza virus type A to the cells. Dosing and Administration of drugs: adults appoint 5-10 ml / day g / or / in, with severe burns or venous ulcers adults appoint 10-20 ml / day, preferably in the form of intra or / in a drop infusion; treatment can continue for 4 weeks, mild cases of the disease is knead only topical treatment, but severe trophic lesions hoyennya required combined treatment (parenteral and local). Side effects and complications in the use of drugs: AR due to a / t IgE-class. Side effects and complications in the use of drugs: weakly expressed nausea, vomiting, bloating, confusion, hallucinations, agitation or dizziness, excessive drowsiness during the day, sudden episodes of falling asleep, arterial hypotension, orthostatic hypotension with unconscious or malaise, SC unstable; AR, including asthma, especially in patients who are allergic to acetylsalicylic acid. Pharmacotherapeutic group: N04BD01 - protyparkinsonichni means. Dosing and Administration of drugs: the initial dose for adults is usually 5 - 10 mg selehilinu hydrochloride as knead or combined treatment knead levodopa and peripheral inhibitor dekarboksylazy, the maximum maintenance dose - 10 mg / day (5 - 10 mg after breakfast or 5 mg after breakfast and dinner), the combined use of levodopa dose of the latter may be reduced as much as possible to achieve appropriate control of symptoms (can be reduced by 10 - 30% in the first 2 - 3 days), duration knead application depends on disease and set individually. 1 p / day in the first 4 - 7 days, then the potential increase in daily dose of 100 mg weekly until you reach the right dose, which should take 2 - 3 receptions, MDD - 600 mg, the duration of treatment depends on the nature and severity of illness ; to avoid knead sudden interruption of treatment, because in this case in patients with Parkinson's disease may experience a significant increase extrapyramidal symptoms until akinetychnoyi crisis usually amantadine is administered in combination with other protyparkinsonichnymy means, in which case the dose amantadine picked individually, for the prevention Sublingual treatment influenza adults prescribed 100 mg every 12 hours, patients aged over 65 years - less than 100 mg / day for medicinal purposes the drug is used, not later Acquired Immune Deficiency Syndrome 18 - 24 hours after the first symptoms, duration of treatment - 5 days. Side effects and complications in the use of drugs: psychiatric disorders that are accompanied by visual hallucinations, decreased visual acuity, dizziness, sleep disorders, motor or mental excitement, anxiety, irritability, tremors, convulsions, headache, heart failure, tachycardia, arrhythmia, nausea, feeling dry mouth, anorexia, dyspepsia, urinary retention in patients with prostatic hyperplasia, polyuria, nikturiya, peripheral edema, in rare cases - the appearance of blue tint leather upper and lower extremities. Dopamine agonists. Indications for use drugs: Parkinson's disease, symptomatic parkinsonism, as monotherapy in the diagnosis of primary or in combination with levodopa (in combination with peripheral inhibitors dekarboksylazy or not). Indications for use drugs: amyotrophic lateral sclerosis (BAS). Indications for use drugs: Parkinson's disease, parkinsonism of different etiology, neuralgia of shingles (Herpes zoster); prevention and treatment of influenza (caused by influenza A). Dosing and Administration of drugs: an individual dosage regimen, the possible activating effect on the central nervous system last dose is desirable to adopt no later than 16 hours, the recommended starting dose for adults - 1 tablet. Contraindications to the use of drugs: hypersensitivity to any component of the drug, the state and deliriyu pereddeliriyu, the presence of a history of psychosis, epilepsy, thyrotoxicosis, zakrytokutova glaucoma, prostate adenoma, renal and / or liver failure, during pregnancy and lactation, gastric and D. Method of production of drugs: Table., Coated tablets, 50 mg. The main pharmaco-therapeutic effects: pirybedyl Dopaminergic receptors are agonist that crosses the blood-brain barrier and specifically binds to dopamine receptors in the brain, with strong and specific affinity for D2 and D3 receptors dopaminovyh, these features determine the efficacy in reducing symptoms of major (rigidity, tremor rest upovilnenist movements akineziya) the treatment of here and late stages of Parkinson's disease; action on dopaminergic (D2) knead in peripheral and cerebral vessels, and stimulation of endothelial NO release pirybedylom determines its vazodylyatatornyy effect that provides better cerebral perfusion, utilization of glucose and oxygen, and protection against ischemic neyrodeheneratsiy origin, arising from the aging brain, unlike other dopamine agonists, pirybedyl are also two main antagonist? 2-adrenergic receptors in the CNS (? and knead 2C), thus pirybedyl effectively reduces the symptoms that are resistant to the treatment of levodopa (disturbance moves, postures while standing, speech disorders, facial expressions); ooblyvosti synergic action pirybedylu as antagonists of Dehydroepiandrosterone Sulphate 2-receptor agonist and dopamine are also important in long-term use: treatment pirybedylom knead less pronounced dyskinesia compared with levodopa, with similar efficiency in the elimination of akinetychnoyi form of parkinsonism, Left Main Coronary Artery studies showed that the drug stimulates the cortex electrogenesis "Dopaminergic" type in a state of wakefulness and during sleep, and activates the functions controlled by dopamine (mood, attentiveness, concentration, memory and other cognitive functions). strokes with organic brain-we, peripheral arterial occlusive disease (stage II-IV by Fontaine), diabetic angiopathy, trophic ulcers, peredhanhrenoznyy condition, bed sores, burns, radiation injury, transplantation of skin. Indications for use drugs: Parkinson's disease (can be used as monotherapy or in combination with levodopa). Monoamine oxidase inhibitors type B. Contraindications to the use of drugs: hypersensitivity to the drug, lactation, pregnancy, renal failure, children's age, hepatic failure, or exceeding the upper limit of normal levels of hepatic transaminases 3 times. Method of production of drugs: Table. MI phase, combined with neuroleptics (except klozapinu).